ArticleCancer causes & control : CCC2025
Estimating the long-term health impact and program cost-effectiveness of providing direct screening services to low-income, medically underserved patients through the Colorectal Cancer Control Program (CRCCP).
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe Colorectal Cancer Control Program (CRCCP) aimed to increase colorectal cancer (CRC) screening among U.S. medically underserved populations through promotion and provision of CRC screening. We used simulation modeling to estimate the lifelong health impact and program cost-effectiveness of direct screening services, typically a single cycle of routine screening/follow-up testing provided through the CRCCP ("intervention").
methodsData for this study were from CDC's Colorectal Clinical Data Elements (CCDE), which captured screening and follow-up services received from CRCCP between 2009 and 2020. We used microsimulation to model the evolution of polyps and CRC for average-risk individuals in intervention and "counterfactual" (control) groups, under multiple scenarios. We calculated and compared lifetime CRC outcomes (cases, deaths, life-years) for individuals with and without the CRCCP intervention. Clinical and implementation costs incurred by the CRCCP were used to estimate programmatic/intervention costs. Results are reported overall and by initial screening modality received (colonoscopy or stool testing) and assumed lower vs. higher "background" (non-intervention) screening scenarios.
resultsWith conservative assumptions, our findings suggest that CRCCP-provided screening averted 806 CRC cases, avoided 392 CRC deaths, and added 5,368 life-years per 100,000 individuals vs. no intervention. Cost-effectiveness analysis revealed that the program's cost per life-year gained varied by screening modality and scenario assumptions-ranging from $25,740 to $27,583 for colonoscopy screening and $70,410 to $75,979 for stool testing.
conclusionCRCCP-provided screening/testing services were found to produce substantial potential health gains. Our analysis estimates the cost-effectiveness of providing one cycle of screening/testing to medically underserved individuals to inform programmatic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.